Management Team

David Weng CEO

  • David Weng is recognized as a seasoned angel and venture investor with a proven track record of bringing startups to successful IPOs, mergers, and acquisitions. He focuses primarily on early-stage investments in the Internet, enterprise software, wireless, cybersecurity, and rapidly-growing technology companies.
  • He has invested in about 80 early-stage high technology companies. Some of the more notable successes include the NetScreen Technologies IPO and its acquisition by Juniper Networks for US$4 billion, and Protego Networks' acquisition by Cisco Systems.
  • Prior to his investment projects, David served as Software Engineering Director at Cisco Systems and at Hewlett-Packard before that. He actively participated in M&A activities during Cisco fast-growing time in the '90s. He has over 20 years of experience in software engineering and Internet technologies.

Jerome Shen, Ph.D. General Partner & Head of Life Science Investments

  • Jerome Shen was the President and co-founder of Allgenesis Biotherapeutics Inc., a new drug development company addressing the unmet medical needs in the ophthalmology areas since 2014. Before Allgenesis, he was the executive of the venture capital firms in Cheng Xin Ventures and Xinchen Ventures for 20 years. He focused on investment in the life science and biotech/pharmaceutical industry and had intensively working experiences with bio-scientific entrepreneurs in startups to help them grow the corporate' value.
  • In addition to the venture capital businesses, he also took the leading roles in several biotech start-ups, responsible for corporate development and strategic initiatives and planning. Dr. Shen was the Secretary-General of Taiwan Biotech Association, a non-profit organization, from 2005 to 2008. The mission of the Taiwan Biotech Association was to provide services to the industry members in business development, human resources, and training programs.
  • He received his Ph.D. in Chemical Engineering at the University of Wisconsin, Madison.

Cathy Chen VP, Administration & Fund Operation

  • Before joining Taiwania Capital in 2018, Cathy was the Chief Financial Officer of CATCHPLAY Group and at the same time served as Special Assistant to the Chairman of TVBS Media Inc. for about 6 years. Before that, she has about 9 years of working experience in Telecom industry (5 years with KG Telecom and 4 years with Taiwan Mobile), and 7 years of working experience in the financial industry (2 years with Citibank Taipei Branch and 5 years with Taiwan Life Insurance Co.).
  • Cathy received her MBA degree from National Chengchi University and a bachelor’s degree from National Taiwan University. She also holds a CPA certificate of Washington State, USA.

Michael Huang Managing Partner

  • Prior to joining Taiwania, Michael was the co-founder and CEO of NeuroVive Pharmaceutical Asia, Inc. (NVP Asia), a new drug development company focusing on the development of mitochondria-related diseases. During his tenure, NVP Asia had successfully signed out-licensing deals with Sihuan Pharmaceutical and Sanofi Korea.
  • Michael had over 18 years of experience as a venture capitalist, focusing on investments in life science startups in the US, Taiwan, and Japan. Some of his notable deals include Coley Pharmaceuticals, Inc. (acquired by Pfizer)、MediciNova (MNOV, OSE:4875)、Nellix, Inc.(acquired by Endologix)、Mycenax Biotech, Inc. (TPEx)、PharmaEngine, Inc. (TPEx)、Apex International Co. (Acquired by Paraxel)、Frequency Therapeuitcs, Inc. (FREQ).
  • Michael's expertise is in investing and managing early to late-stage biotech and medical device companies in Greater China, Japan, European and North America regions.

Huang Lee, Ph.D. Managing Partner

  • Dr. Lee serves as the Managing Partner of Taiwania Capital in Silicon Valley, where he focuses on enterprise software, autonomous systems, advanced manufacturing, robotics & drones, next-gen semiconductors, sensors, immersive technology, 5G, and cloud infrastructure. He serves as the board of directors of several startups in Silicon Valley and is the advisor and former President of TAITA, one of the largest Taiwanese organizations connecting entrepreneurs, technologists, and investors between Taiwan and Silicon Valley. Dr. Lee was trained as an engineer and has published 50+ papers and patents with 1000+ citations. He received his Ph.D. from Stanford University.

Ita Lu Managing Partner

  • Prior to joining Taiwania, Ita has combined 20 years of both life sciences buy-side (public equities, venture capital, private equity), sell-side (equity research, investment banking) and biotech operational experiences across the US and in Asia. Ita's investment expertise across both direct investment as well as the secondary market in investing and managing expansion to late-stage biotech and medtech companies.
  • Some of his notable deals include Advancis Pharmaceuticals (IPO), PTC Therapeutics (IPO), Anadys Pharmaceuticals (Acquired by Roche), Arpida AG (IPO), CombinatoRx (IPO), Morphotek (Acquired by Eisai), U-Systems (Acquired by GE Healthcare), MBI Biotech (IPO) , PharmaEssentia (IPO) and Eirgenex (IPO).